Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Filings indexed 534 across all filing types
Latest filing 2026-03-18 Regulatory Filings
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
15-12G - RAPT Therapeutics, Inc. (0001673772) (Filer)
Regulatory Filings
2026-03-18 English
8-K - RAPT THERAPEUTICS, INC. (0001673772) (Filer)
Regulatory Filings
2026-03-03 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
SCHEDULE 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)
Major Shareholding Notification
2026-02-09 English
4 Filing
Director's Dealing
2026-02-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.